Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is 17.04.
Forward PE Ratio (17.04) = Close Price ($393.17) / Consensus Forward EPS ($23.08)
FORWARD PE RATIO
17.04
SECTOR MEDIAN · HEALTHCARE
20.01
median of 78 covered companies
CURRENT VS SECTOR MEDIAN
-14.84%
vs the sector median at left
Amgen Inc.
Market Cap
$212.20B
Forward PE Ratio
17.04
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Amgen Inc. (AMGN) | $212.20B | 17.04 |
| Novo Nordisk A/S (NVO)vs › | $200.54B | N/A |
| Thermo Fisher Scientific Inc. (TMO)vs › | $224.09B | 24.44 |
| Abbott Laboratories (ABT)vs › | $182.59B | 19.13 |
| Gilead Sciences, Inc. (GILD)vs › | $182.06B | N/A |
| AstraZeneca PLC (AZN)vs › | $248.20B | 15.63 |
| Pfizer Inc. (PFE)vs › | $158.39B | 9.57 |
| Danaher Corporation (DHR)vs › | $144.25B | 24.42 |
| Vertex Pharmaceuticals Incorporated (VRTX)vs › | $134.24B | 29.13 |
| Bristol-Myers Squibb Company (BMY)vs › | $132.14B | 9.34 |
Trailing P/E
24.4
reported TTM EPS
Forward P/E
17.0
consensus next-FY EPS
The gap between the two multiples is the consensus growth expectation: analysts' forward EPS of $23.08 implies +43.4% EPS growth vs the reported trailing $16.09.
At today's $393.17 close, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $23.08 | $22.57 – $23.61 | 19 | 17.0x |
| 2027-12-31 | $24.43 | $22.60 – $25.65 | 19 | 16.1x |
| 2028-12-31 | $25.74 | $21.64 – $29.18 | 11 | 15.3x |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
